ScoreWhy is Concord Biotech Ltd ?
1
High Management Efficiency with a high ROE of 17.91%
2
The company is Net-Debt Free
3
Poor long term growth as Net Sales has grown by an annual rate of 8.53% and Operating profit at 1.80% over the last 5 years
4
Negative results in Jun 26
- ROCE(HY) Lowest at 17.24%
- PBT LESS OI(Q) At Rs 65.51 cr has Fallen at -11.3% (vs previous 4Q average)
- PAT(Q) At Rs 58.53 cr has Fallen at -11.1% (vs previous 4Q average)
5
With ROE of 13.1, it has a Very Expensive valuation with a 7 Price to Book Value
- The stock is trading at a fair value compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -16.26%, its profits have fallen by -22%
6
Majority shareholders : Promoters
7
Underperformed the market in the last 1 year
- Even though the market (BSE500) has generated returns of 4.11% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -16.26% returns
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Concord Biotech should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Concord Biotech for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Concord Biotech
-16.26%
-0.41
39.61%
Sensex
-2.63%
-0.19
13.57%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
8.53%
EBIT Growth (5y)
1.80%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.20
Sales to Capital Employed (avg)
0.64
Tax Ratio
25.09%
Dividend Payout Ratio
24.63%
Pledged Shares
0
Institutional Holding
16.88%
ROCE (avg)
27.54%
ROE (avg)
17.91%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
51
Industry P/E
37
Price to Book Value
7.02
EV to EBIT
43.83
EV to EBITDA
35.39
EV to Capital Employed
8.57
EV to Sales
12.40
PEG Ratio
NA
Dividend Yield
1.35%
ROCE (Latest)
18.27%
ROE (Latest)
13.06%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Bullish (Daily)
KST
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend0What is working for the Company
NO KEY POSITIVE TRIGGERS
-10What is not working for the Company
ROCE(HY)
Lowest at 17.24%
PBT LESS OI(Q)
At Rs 65.51 cr has Fallen at -11.3% (vs previous 4Q average
PAT(Q)
At Rs 58.53 cr has Fallen at -11.1% (vs previous 4Q average
DEBTORS TURNOVER RATIO(HY)
Lowest at 2.29 times
Loading Valuation Snapshot...
Here's what is not working for Concord Biotech
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 65.51 cr has Fallen at -11.3% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 73.89 CrMOJO Watch
Near term PBT trend is very negative
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 58.53 cr has Fallen at -11.1% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 65.83 CrMOJO Watch
Near term PAT trend is very negative
PAT (Rs Cr)
Debtors Turnover Ratio- Half Yearly
Lowest at 2.29 times
in the last five half yearly periodsMOJO Watch
Company's pace of settling its Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
